G
GeoVax Labs, Inc. (GOVX)
NCM – Real Time Price. Currency in USD
1.37
-0.11 (-7.43%)
At close: May 12, 2026, 4:00 PM EDT
1.30
-0.07 (-5.11%)
After-hours: May 12, 2026, 5:56 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.37
-0.11 (-7.43%)
At close: May 12, 2026, 4:00 PM EDT
1.30
-0.07 (-5.11%)
After-hours: May 12, 2026, 5:56 PM EDT
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
| Name | Position |
|---|---|
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Mr. David Alan Dodd | Chairman, President & CEO |
| Mr. Jeffrey Welch | Head of Process Development & Manufacturing Operations |
| Mr. Mark W. Reynolds CPA | CFO & Corporate Secretary |
| Mr. Thomas O'Brien | Vice President of Quality Systems & Compliance |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | PRER14A | govx-20251231.htm |
| 2026-05-07 | 8-K | govx20260507_8k.htm |
| 2026-04-27 | DEF 14A | govx20260421_def14a.htm |
| 2026-04-17 | POS EX | govx20260417c_posex.htm |
| 2026-04-16 | PRE 14A | govx20260412_pre14a.htm |
| 2026-04-16 | POS AM | govx-20251231.htm |
| 2026-04-15 | 8-K | govx20260415_8k.htm |
| 2026-03-31 | NT 10-K | govx20260330_nt10k.htm |
| 2026-03-31 | 8-K | govx20260331_8k.htm |
| 2026-02-17 | 8-K | govx20260217_8k.htm |